Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus.

Autor:	Zhu B; Department of Epidemiology and Statistics, North China University of Science and Technology, Tangshan, China., Lv X; Preventive Health Branch, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China., Zhao Z; Preventive Health Branch, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China., Chen L; Preventive Health Branch, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China., Chen X; Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, China., Li C; Preventive Health Branch, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China., Li S; Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, China., Dai E; Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, China.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2021 Nov 05; Vol. 100 (44), pp. e27695.
DOI:	10.1097/MD.0000000000027695
Abstrakt:	Abstract: The present study is aimed to evaluate and compare the efficacy and safety of tenofovir (TDF) and telbivudine (TBV) in interrupting hepatitis B virus (HBV) mother-to-child transmission (MTCT), and to provide evidence-based treatment options to clinicians and patients.Hepatitis B e-antigen (HBeAg)-positive pregnant women (644 in total) with high HBV DNA load (≥2 × 105 IU/mL) and who received TDF (n = 214) or TBV (n = 380) in the second or third trimester, or received no treatment (n = 50) were included in this retrospective analysis.HBV DNA levels in mothers at delivery were significantly lower than baseline in the 2 treatment groups. HBV DNA levels in the TDF group were significantly different between the mothers receiving treatment in the second trimester and those receiving treatment in the third trimester; however, significant difference was not observed in the TBV group. The proportion of hepatitis B surface antigen (HBsAg)-positive infants at the age of 7 to 12 months in the TDF, TBV, and control groups were 0.00% (0/174), 0.30% (1/331), and 5.0% (2/40) with a significant difference between the treatment groups and the control group, but no difference between the TDF and TBV group (P > .05). However, no serious adverse events were observed in infants and mothers of all groups.TBV and TDF can effectively reduce the HBV DNA level and MTCT rate in pregnant women with high HBV DNA load (≥2 × 105 IU/mL); both antiviral drugs are safe for infants and mothers. Since TDF was more effective in reducing HBV DNA levels during the second trimester, its use during the period is recommended to prevent HBV MTCT. Competing Interests: The authors have no conflicts of interests to disclose. (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu